CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
|Articles|November 1, 2001
Supplements and Featured Publications
- New Directions in the Treatment and Prevention of Deep Vein Thrombosis
- Volume 7
- Issue 17 Suppl
Interview
Advertisement
Articles in this issue
almost 25 years ago
Participating Facultyalmost 25 years ago
Introductionalmost 25 years ago
Treatment of Deep Vein Thrombosis Using Low-Molecular-Weight Heparinsalmost 25 years ago
Prophylaxis Strategies for Patients with Acute Venous Thromboembolismalmost 25 years ago
Continuing Medical Education Quizalmost 25 years ago
Literature ReviewAdvertisement
Related to this article
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
5